Compare Bristol-Myers Squibb Co (BMY) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Las Vegas Sands Corp. — how do they compare? Bristol-Myers Squibb Co trades at $58.44 (market cap $116.30B), while Las Vegas Sands Corp. trades at $44.7 (market cap $29.67B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.9× Las Vegas Sands Corp.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | LVS | |
|---|---|---|
Market Cap | $116.30B | $29.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $69.49 |
52-Week Low | $42.60 | $44.78 |
Enterprise Value | $152.24B | $42.07B |
Dividend Yield | 4.42% | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
LVS trades at $45.90, down 1.69% on the day, with a bearish technical signal despite strong fundamentals. The company reported Q1 2026 revenue of $3.59 billion, up 25.3% year-over-year, and EPS of $0.91, beating estimates. Analyst consensus is strongly bullish with a $65.56 price target, though technical indicators show selling pressure near key support at $45.
LVS presents a compelling value opportunity with a P/E of 16.94 and consistent earnings beats, but faces headwinds from high debt levels and bearish technical momentum. Upside potential exists if the stock holds support and executes on growth, while downside risk persists if macroeconomic or regulatory pressures intensify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
